You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 28 results found

Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof

The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.
  • Therapeutics

MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury

Researchers at the NICHD developed a method for non-invasively determining the distribution of pore lengths and radii within a matrix thereby characterizing cognitive defects observed in patients with Traumatic Brain Injury (TBI). The NICHD seeks licensing and/or co-development research collaborations to bring this invention to the public.
  • Diagnostics

Tamperless Tensor Elastography Imaging

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamperless tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
  • Diagnostics

Systems and Devices for Training and Imaging an Awake Test Animal

Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
  • Devices

Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel

Hibernation in mammals is a seasonal state of metabolic suppression and dormancy characterized by a decrease in body temperature to survive extreme environmental stresses. A new Induced Pluripotent Stem Cell (iPSC) line has been established from the neural precursor cells of wild type thirteen-lined ground squirrel (Spermophilus tridecemlineatus), a small mammalian hibernator with unique metabolic adaptations for coping with cold and restricted food supply. This ground squirrel iPSC line can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening for neuronal injuries or other diseases.
  • Research Tools

Device for Simulating Explosive Blast and Imaging Biological Specimens

Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.
  • Devices

Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use

Scientists at the National Institute on Drug Abuse (NIDA) have developed novel dopamine D3 receptor (D3R) agonists with high affinity and selectivity. Two lead compounds, 53 and eutomer 53a, have demonstrated significantly higher D3R binding selectivity than reference compounds. Moreover, 53 and 53a showed metabolic stability in liver microsomes, which is favorable for the future use of these compounds as therapeutic agents for diseases related to dopamine system dysregulation such as Parkinson’s Disease and Restless Legs Syndrome. Researchers at NIDA seek licensing and/or co-development research collaborations for the use of these D3R agonists as molecular tools for the study of D3R physiology and as potential therapeutics to treat neurological and neuropsychiatric disorders.
  • Therapeutics

Margaric Acid Decreases PIEZO2 Mediated Pain

Investigators at the National Center for Complimentary and Integrative Health (NCCIH) and the University of Tennessee Health and Science Center have shown that administration of margaric acid can ameliorate pain induced by a variety of noxious stimuli in mice. In vitro and ex vivo studies in human and murine neural cells indicate that the mechanism of action of margaric acid is mediated by PIEZO2 (Piezo-type mechanosensitive ion channel component 2) function. NCCIH seeks research co-development partners and/or licensees for methods of using the fatty acid, margaric acid to treat pain.
  • Therapeutics

Isotropic Generalized Diffusion Tensor MRI

The Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) seeks research and co-development partners or licensees for an invention that discloses the diagnosis of pathologies in tissue related to changes in cell size, cellularity, cell infiltration, and other abnormalities detected by bulk water diffusion changes.
  • Software

Polymeric Delivery Platform for Therapeutics

The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
  • Therapeutics

Pages